Latest News about IBB
Recent news which mentions IBB
From Benzinga
From Benzinga
Here’s one for the battered bulls: the second-largest sector in the S&P 500 is stirring to life, says this strategist.
March 22, 2023
From MarketWatch
US Judge Weighs Nationwide Ban On Abortion Pills
March 16, 2023
From Benzinga
From InvestorPlace
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
March 13, 2023
From Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
March 10, 2023
From Benzinga
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
March 10, 2023
From Benzinga
From Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
March 07, 2023
From Benzinga
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
March 01, 2023
From Benzinga
The stock market’s January rally was real, and these stocks and ETFs can help you ride the next leg up
February 22, 2023
From MarketWatch
From InvestorPlace
From Benzinga
The 3 Best Biotech Stocks Under $1 to Buy for January
January 26, 2023
From InvestorPlace
From Benzinga
From Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
What the end of the stock market’s ‘FANG-era’ means for ETFs
December 22, 2022
From MarketWatch
Look to SBIO for Biotech Exposure
December 12, 2022
From ETF Trends
From Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
From Benzinga
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 01, 2022
From Benzinga
Chart of the Week: What Sector Looks Healthiest to Advisors
November 10, 2022
From ETF Trends
‘Just so full of autocracies’: For the Freedom 100 Emerging Markets ETF, outperformance in 2022 goes beyond nixing China
November 03, 2022
From MarketWatch
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
These 4 ETFs Feature on CNBC's 'Final Trades'
October 27, 2022
From Benzinga
SBIO Rallied While Major Indexes Declined Last Week
October 04, 2022
From ETF Trends
From Benzinga
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
September 27, 2022
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.